5 year sustained efficacy of Gardasil®

5 year sustained efficacy of Gardasil®, the first and only vaccine available to prevent cervical cancer.

5 year sustained efficacy of Gardasil®, the first and only vaccine available to prevent cervical cancer.

Maidenhead, 6th December 2006 - A long term follow up study published in the online edition of the British Journal of Cancer showed that Gardasil® prevented 100% of pre-cancerous cervical lesions and genital warts related to Human Papillomavirus types 6, 11, 16 and 18 for up to five years, compared to placebo.  Pre-cancerous cervical lesions (Cervical Intraepithelial Neoplasia grade 2/3 - CIN2/3) are the immediate precursors of invasive cervical cancer.

"These results are very important. High and consistent efficacy has been observed for five years and is expected to be long-lasting," commented Dr Mike Watson, Executive Director European Clinical and Epidemiology, Sanofi Pasteur MSD.

Gardasil® is now available in the United Kingdom, having received a European licence on 20th September 2006. Gardasil® is also available in a number of European countries including Ireland, France and Germany and other countries will follow soon. National health authorities including the UK’s Joint Committee on Vaccination and Immunisation (JCVI) are in the process of discussing vaccination recommendations and funding procedures for Human Papillomavirus vaccination. Decisions are expected in the near future.

Gardasil® is licensed for children and adolescents aged 9 to15 years and adult females aged 16 to 26 years for the prevention of:

-       cervical carcinoma (cervical cancer)

-       high grade cervical dysplasia (CIN 2/3)

-       high grade vulvar dysplastic lesions (VIN 2/3)

-       external genital warts (condyloma acuminata)

caused by Human Papillomavirus types 6, 11, 16 and 18.

- ends -

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Face-to-face GP appointments on demand 'unachievable', warns RCGP chair

Face-to-face GP appointments on demand 'unachievable', warns RCGP chair

Calls for general practice to offer face-to-face appointments to all patients who...

Cornwall PCN wheels out electric car fleet to reduce carbon footprint

Cornwall PCN wheels out electric car fleet to reduce carbon footprint

Staff at a primary care network (PCN) in Cornwall have committed to reducing their...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Repeat prescribing and SMR overhaul as review finds one in 10 scrips unnecessary

Repeat prescribing and SMR overhaul as review finds one in 10 scrips unnecessary

Repeat prescribing and use of structured medication reviews in general practice are...

BMA demands emergency meeting with government over GP abuse

BMA demands emergency meeting with government over GP abuse

BMA leaders have requested an emergency summit with the government to discuss ‘unacceptable...

Millions of pounds lost to general practice as flagship recruitment scheme falls short

Millions of pounds lost to general practice as flagship recruitment scheme falls short

Tens of millions of pounds in funding from a flagship recruitment scheme set up to...